Poly Medicure Limited · NSE:POLYMED
Poly Medicure — Investor Presentation (May 2021)
38 slides from Poly Medicure's investor presentation, May 25, 2021
Slide 1: Regulation 30 cover letter for Investor Presentation FY 2020-21
Poly Medicure Limited Regd . Office : 232- B, 3'' Floor, Okhla Industrial Estate, Phase-Ill, New Delhi - 110020 (INDIA) p IYMED M E D !CAL DEVICES T:+91-ll -33550700,47317000, F: +91-ll-26321894,26321839 We Care As We Cure E: info@polymedicure.com W: polymedicure.com GIN : L 40300DL l 995PLC066923 D
Slide 2: Uniquely positioned to deliver value and solutions beyond the device
Uniquely positioned to deliver value and solutions “beyond the device.” May 2021 w w w . po l ym ed i cu re . co m
Slide 3: Disclaimer
DISCLAIMER This presentation has been prepared by Poly Medicure Limited (the “Company”) solely for your information and may not be distributed, reproduced, or redistributed or passed on directly or indirectly to any other person, whether within or outside your organization or firm, or published in w
Slide 4: Content
Content Our Journey Management Corporate Structure Polymed’s Unique Position Executive Leadership Demographics and Industry Trends Five Year Vision Customer Stickiness, Sustainable Business Manufacturing, R&D and Regulatory Capabilities Key Financials and Ratios New Product launches Medical Educatio
Slide 5: Our Journey: Milestone Achievements
OUR JOURNEY…..…..MILESTONE ACHIEVEMENTS 1997 2001 2002 2004 2006 2007 2009 Commencement of Expansion of JV in Egypt Faridabad Plant-2 Acquired 75% of New Plant China Plant Manufacturing Faridabad Plant Extension (100% US Safety Haridwar Operation EOU) Syringes 2011 2014 2016 2018 2020 2021 *2022 *20
Slide 6: Across the world, we serve people in over 110+ countries
ACROSS THE WORLD, WE SERVE PEOPLE IN OVER 110+ COUNTRIES 9 Manufacturing Plants* (*2 under construction) 1 R&D Center UNIQUELY POSITIONED TO PROVIDE VALUE TO OUR CUSTOMERS Confidential I Slide 2
Slide 7: Board of Directors & Management
BOARD OF DIRECTORS & MANAGEMENT Mr. Devendra Raj Mehta (Chairman, Non Executive Independent Director) Mr. Himanshu Baid Mr. Rishi Baid (Managing Director) (Joint Managing Director) Mr. Jugal Kishore Baid Mrs. Mukulika Baid Dr. Shailendra Raj Mehta (Non Executive Director) (Non Executive Director) (N
Slide 8: Corporate Structure
CORPORATE STRUCTURE POLYMED GROUP INDIA OVERSEAS Poly Medicure Poly Medicure BV - Ultra for Medical Poly Medicure Ltd (Laiyang) Co. Ltd. - Netherlands - Products Co. China - Wholly Wholly owned (UMIC) - Egypt owned Subsidiary Subsidiary Associate Plan 1 Health India Pvt. Ltd. - Wholly owned Plan 1 H
Slide 9: Polymed's Unique Position
POLYMED’S UNIQUE POSITION EMINENCE IN FLUID MANAGEMENT DISPOSABLES AND PROCEDURAL MEDICAL DEVICES COMPREHENSIVE PRODUCT RANGE INNOVATION, AN INTEGRAL PART OF POLYMED STORY Oncology Infusion & Vascular Access Amongst the Top 3 I.V. Cannula Manufacturer in the world 1st In India Diagnostics Gastroentr
Slide 10: Strong Executive Global Leadership Added
STRONG EXECUTIVE GLOBAL LEADERSHIP ADDED BUILDING OUT GEOGRAPHICAL LEADERSHIP WITH DEEP MEDICAL DEVICE EXPERIENCE AND EXPERTISE Xue Wendong General Manager China • 20 years Medical Device Experience • Managing Polymed China Kim Schelble Facility VP & Managing Director N. America • 14 years Medical D
Slide 11: India Business Leadership
INDIA BUSINESS LEADERSHIP LEADERSHIP WITH DEEP MEDICAL DEVICE EXPERIENCE AND EXPERTISE Vishal Baid Naresh Vijay President President, Finance & Strategy P K Gupta New Delhi Manish Sardana President, India Business Associate Vice President, Operations SS Rawat Sujit Gupta Associate Vice President, Exp
Slide 12: Indian Medical Devices Market
INDIAN MEDICAL DEVICES MARKET 4th $11 Bn 9-11% $50 Bn Largest Market in in Current Market Size CAGR Growth Market Size by 2025 Asia After Japan, China Including implants, Over the period of 5 Poised to be the & South Korea consumables, years leader in Medical Medical Electronics Devices Gove
Slide 13: 2020-2025 Vision
2020-2025 VISION TRANSFORM FROM A PRODUCT COMPANY TO A SOLUTION PROVIDER ORGANIZATION Started in 1997 2002-2009 2011-2019 2020-2021 2022-2025 2026 and beyond Commencement of Product and facility New R&D Center Focus on commercial Launch differentiated Globally recognized Manufacturing expansion Acq
Slide 14: Stickiness in Customer Base & Sustainable Business
STICKINESS IN CUSTOMER BASE & SUSTAINABLE BUSINESS LEVERAGE OUR (CUSTOMER) INSTALLED BASE AND DISTRIBUTOR NETWORK TO LAUNCH NEW PRODUCTS Strong Repeat Orders & Large Strategic Customer Base Relationships Meaningful Relationships Large customer base over 110 150+ commercially available Long ten
Slide 15: Manufacturing Across Four Countries
MANUFACTURING ACROSS FOUR COUNTRIES (INDIA, ITALY, EGYPT, CHINA) 1 st Medical Device Company from India to have overseas plants. Faridabad Plant, India Haridwar Plant, India IMT Faridabad India Over 250+ Moulding Machines & 800+ Injection Molds More than 150+ automatic assembly machines with Faridab
Slide 16: R&D, Regulatory and Process Capabilities
R&D, REGULATORY AND PROCESS CAPABILITIES FULLY INTEGRATED FROM NEW PRODUCT DESIGN DEVELOPMENT TO AUTOMATED MANUFACTURING 310+ Patents & 160+ pending applications R&D Team with 50+ engineers and 10+ Clinical Consultants All products are CE certified (EU Regulatory Compliant) • Regulatory team s
Slide 17: Our Strength: Consistent All round growth (Consolidated)
Our Strength: Consistent All round growth (Consolidated) ₹ ₹ REVENUE (₹ Crs) EBIDTA (₹ Crs) 160.00 PAT (₹ Crs) 135.84 1000 250 140.00 214.34 786.20 120.00 800 687.24 200 95.88 163.96 100.00 610.83 600 461.86 521.68 150 120.34 129.45 80.00 70.59 65.40 91.72 55.13 400 100 60.00 40.00 200 50 20.00 0 0
Slide 18: Fund Raise Journey
FUND RAISE JOURNEY 2021 QIP 1996 400 IPO Crs 2.65 Crs Confidential I Slide 14
Slide 19: QIP Fund Raise
QIP QIP FUND RAISE Institutional Demand 2029 Acquisition opportunities India and Crs Overseas Expansion of existing Business New Production facilities Target Fund Raise Rs 400 Crs QIP No of Meetings/ Roadshows 52 Investment in Subsidiaries Allotment at Rs 524/Share 6 New Investors Repaymen
Slide 20: Major Participants
MA JOR P A RTI CI PI ANTS Curated Roadshows Covering Major Investors Across the Globe 1X1 Investor Meetings UTI MF Light House Capital Research White Oak Max Life IIFM AMC SBI MF ICICI Pru MF GSAM Fidility Param Capital Taiyo Pacific Sundaram MF T Rowe Price Mirae MF Grandeur Peak Ashmore Malabar Sa
Slide 21: QIP New Stakeholders
QIP NEW STAKEHOLDERS In Rs Crs Shareholding-Adding Institutional Shareholders 60.00 48.76 50.00 44.88 40 9 109 62 40.00 28.39 30.00 24.89 71 109 20.00 15.12 17.64 15.11 10.00 5.21 0.00 Promoters Institutional Private Corporate Indian public Capital group White Oak group Investors Bodies UTI MF Light
Slide 22: Creating Value for Shareholders
Creating Value for Shareholders Increasing Shareholders Base Creating Value for Shareholders NO. OF SHAREHOLDERS MARKET CAP IN CRS 25000 9000 21531 7884.74 8000 20000 7000 6000 15000 5000 4000 10000 8574 3000 2056.36 2000 5000 1000 0 0 No of Shareholders Market Cap 31-03-2020 31-03-2021 31-03-2020 3
Slide 23: Ratios
RATIO’S Interest Coverage Debt Service Coverage 35 6 5.57 5.54 5.55 29.58 30 5 4.44 4.61 25 4 20 14.32 3 15 10.8 10.49 8.52 2 10 5 1 0 0 % % FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 ROCE ROE 30.00% 20.62% 21.02% 19.38% 21.03% 40.00% 20.00% *15.98% 23.46% 24.51%
Slide 24: Performance Standalone/Subsidiary
Performance Standalone/Subsidiary Poly Medicure Ltd Subsidiaries Standalone 45.00 Poly Medicure 800.00 747.38 41.08 39.09 (Laiyang) Co. Ltd. - 40.00 700.00 China - Wholly 646.16 owned Subsidiary 35.00 586.69 600.00 30.00 500.00 24.13 Poly Medicure BV - 25.00 Netherlands - 400.00 20.00 Wholly owned 1
Slide 25: Grew our distributor network extending our customer reach
Grew our distributor network extending our customer reach Intensive Care Unit Increased Distributor Expanding Footprints Network Dialysis Section Critical Care Unit Distributor strength increased from 150 to 223 Added top corporate hospitals, dialysis & lab chains IPD Wards Emergency Strengthe
Slide 26: HCP Connect
HCP Connect Webinars | Focused Communication | Posts I Personalized e-Greetings | Contest I AVs Webinars Direct Communication Campaigns Important Medical Days, New Product Launch, Marketing campaigns 10 73 10 Webinar links Blood Donor Week Total 93 webinars organized, eMail, Whatsapp – 25,000
Slide 27: New Products Plan for FY 21-22
New Products Plan for FY 21-22 Alcohol Prep Pad PolySwab- Disinfectant cap Single use dialyzer Nebulizer Machine ECG- Electrode Syringes Blood Bag with LD filter Confidential I Slide 25
Slide 28: New Products Plan for FY 21-22 (Diagnostics)
New Products Plan for FY 21-22 (Diagnostics) RT-PCR Kit RNA extraction Kit COVID-19 antigen Kit COVID-19 Range Confidential I Slide 26
Slide 29: New Products Plan for FY 21-22 (Diagnostics)
New Products Plan for FY 21-22 (Diagnostics) Dengue NS1 antigen detection Dengue NS1 Ag and IGG/IGM Dengue IGM/IGG Malaria Ag P.f/Pan Typhoid Rapid Igg/Igm Troponin I (Cardiac Marker) Confidential I Slide 27
Slide 30: Business Growth – Region wise Performance
Business Growth – Region wise Performance Growth in Sales (% wise) – Compared to Last FY 2019-20 MIDDLE EAST EUROPE & CIS AFRICA SOUTH EAST ASIA AMERICAS INDIA Confidential I Slide 28
Slide 31: International Biz – Digital Engagements
International Biz – Digital Engagements Participated in Virtual Exhibitions MEDICAL DEVICES EXPO 2021 VIRTUAL MEDICA 2020 Confidential I Slide 29
Slide 32: International Biz – Digital Engagements
International Biz – Digital Engagements ELEVATE : Virtual Global Training Program DIGITAL INTERACTIONS WITH INTERNATIONAL CLIENTS Confidential I Slide 30
Slide 33: International Biz – Value Drivers
International Biz – Value Drivers Complete Line of Peripheral & Central Lines New Vascular Access & Infusion Accessories Full range of peripheral and central lines to offer to Complimentary vascular access and infusion accessories customers to complete their product portfolio Bid for large Ten
Slide 34: Production Linked Incentive Scheme
PRODUCTION LINKED INCENTIVE SCHEME Government has earmarked a Budget of 3420 Crs. for the scheme • Polymed got approval under Renal Care Segment for following products Dialyzer Dialysis Machine Peritoneal Dialysis Kit Bloodline Fistula Transducer Protector • Greenfield projects defined u
Slide 35: CapEx update
CapEx update Particulars Total Capex Planned Capex incurred in for 2020-21 2020-21 Expansion at SEZ, Jaipur 15.00 8.91 Expansion Plant at IMT, Faridabad 33.00 34.97 Balancing Expansion at Unit I+II, Faridabad 27.00 24.49 Balancing Expansion at Haridwar 12.60 13.29 New Plot Sector 56 A Faridabad 13.4
Slide 36: Covid-19 update and company's actions
Covid-19 update and company’s actions IMPACT ACTIONS Increased Material Cost Managing Operations with COVID Protocol Increased Logistics Cost COVID Awareness Programs for Employees Limited availability of Vessels/Air Cargo Increased COVID specific CSR spent. Reduced manpower Added CO
Slide 37: Awards & Recognition
Awards & Recognition “BEST UNDER A BILLION” “ATMANIRBHAR MEDTECH CO.” Forbes Asia "TORCHBEARER OF HEALTHCARE” “CFO AWARD” "TOP EXPORTER AWARD” Medgate Today Medgate Today Plastic Export Promotion Council Financial Express Confidential I Slide 35
Slide 38: Thank You
Poly Medicure Limited Thank You Registered Office: 232 B, 3rd Floor, Okhla Industrial Estate, Phase III, New Delhi-110020, India Tel:- 91-11-33550700, 47317000, 26321838/99 For any general queries, Reach us at: info@polymedicure.com Visit: www.polymedicure.com